Sinusitis News
-
Infrared Coagulation of The Inferior Turbinate: A new treatment for refractory chronic rhinitis
Nasal obstruction remains a challenge to the modem day rhinologist. In the evolving climate of "cost containment" and "risk-outcome analyses", office-based inferior turbinate reduction has regained popularity. This article describes a new method to reduce nasal obstruction in patients with chronic rhinitis when conventional medical therapy has failed. Rhinitis is chronic (CR) when symptoms of ...
-
Successful SARS-CoV-2 trial with Ondine’s nasal photodisinfection
Clínica Universidad de Navarra has completed a randomised controlled study of Ondine Biomedical’s nasal photodisinfection technology in fully vaccinated COVID-19 patients with early symptoms of COVID-19. “Top-line results from this clinical trial suggest that nasal photodisinfection treatment rapidly and substantially suppresses SARS-CoV-2 viral replication and infectivity in ...
-
WHO calls for new innovations to tackle antimicrobial resistance crisis
Antimicrobial resistance (AMR) threatens the effective prevention and treatment of an ever-increasing range of infections caused by bacteria, parasites, viruses and fungi Ondine’s nonantibiotic photodisinfection technology has been proven in Canadian hospitals to kill pathogens helping to generate 84% reduction of postoperative infection rates and significant cost savings. The World ...
-
Health Canada Grants Marketing Authorization for TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in Children With Cystic Fibrosis Ages 6 Through 11 years With At Least One F508del Mutation
Approximately 500 Canadians ages 6-11 are now eligible for TRIKAFTA®- Vertex has submitted this indication to CADTH & INESSS for Health Technology Assessments- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Health Canada has granted Marketing Authorization for the expanded use of TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) to include ...
-
FDA Accepts Dupixent (dupilumab) for Priority Review in Patients Aged 12 Years and Older with Eosinophilic Esophagitis
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for Dupixent® (dupilumab) 300 mg weekly to treat adult and pediatric patients aged 12 years and older with eosinophilic esophagitis (EoE), a chronic and progressive type 2 inflammatory ...
-
Dupixent (dupilumab) Approved by European Commission for Children Aged 6 to 11 Years with Severe Asthma with Type 2 Inflammation
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the European Commission (EC) has expanded the marketing authorization for Dupixent (dupilumab) in the European Union. Dupixent is now also approved in children aged 6 to 11 years as an add-on maintenance treatment for severe asthma with type 2 inflammation characterized by raised blood eosinophils and/or raised ...
-
Vaxcyte Doses First Participants in Phase 2 Portion of Ongoing VAX-24 Phase 1/2 Clinical Proof-of-Concept Study in Adults
Following Prespecified Review of Phase 1 Safety and Tolerability Data, Independent Data Monitoring Committee Recommends Study Proceed as Planned Company Expects to Announce Topline Results from Both the Phase 1 and Phase 2 Portions of the Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease and Pneumonia by the End of 2022 VAX-24 is a 24-Valent Pneumococcal Conjugate ...
-
Creative Enzymes Introduces Chitinases for Research and Industrial Production
Creative Enzymes, a professional enzyme provider located in New York, USA, is always hammering away at research and trials in order to provide customers with as many enzyme services and products as possible. Creative Enzymes recently announced Chitinases for research and industrial production. Chitin widely exists in the shells of crustaceans, the carapaces of insects and the cell walls of ...
-
Vaxcyte Doses First Participants in Phase 1/2 Clinical Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults
Company Expects to Announce Topline Results from the Phase 1/2 Study by the End of 2022 Proof-of-Concept Study Will Evaluate the Safety, Tolerability and Immunogenicity of VAX-24 VAX-24 is a 24-Valent Pneumococcal Conjugate Vaccine Designed to Deliver Broad-Spectrum Protection Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to ...
-
Real-World Evidence Study Demonstrates Intersect ENT’s PROPEL Sinus Implant Reduces Healthcare Resource Utilization
Real-World Evidence Study Demonstrates Intersect ENT’s PROPEL® Sinus Implant Reduces Healthcare Resource Utilization Data from first-of-its-kind study published in Current Medical Research and Opinion Patients receiving PROPEL® following endoscopic sinus surgery had statistically significant lower healthcare resource utilization over a postoperative period of 18 months, ...
-
Lyra Therapeutics Announces Initiation Of Lyr-210 Pivotal Phase 3 Enlighten Program In Surgically Naïve Chronic Rhinosinusitis Patients
LYR-210 and LYR-220 are designed to complement each other in addressing the broad spectrum of CRS patients treated by ENT Physicians Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company leveraging its proprietary XTreo™ platform to enable precise, sustained, and local delivery of medications to the ear, nose and throat (ENT) passages and other diseased tissues, ...
-
Vaxcyte Announces FDA Clearance of Investigational New Drug Application for VAX-24 for the Prevention of Invasive Pneumococcal Disease
Company Expects to Deliver Topline Immunogenicity Results from the Phase 1/2 Clinical Study by End of 2022 VAX-24 is a 24-Valent Pneumococcal Conjugate Vaccine Candidate Designed to Provide Broad-Spectrum Protection Vaxcyte, Inc. (Nasdaq: PCVX), a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, announced today ...
-
Lyra Therapeutics to Present at Upcoming Virtual Investor Conferences
Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company leveraging its proprietary XTreo™ platform to enable precise, sustained, and local delivery of medications to the ear, nose and throat (ENT) passages and other diseased tissues, today announced that Maria Palasis, Ph.D., Lyra's President and Chief Executive Officer, will present in a virtual format at three ...
-
First Implants of PROPEL Contour in Patients with Chronic Rhinosinusitis Following Frontal Sinus Surgery in Europe
Intersect ENT®, Inc. (Nasdaq: XENT), a global ear, nose and throat (“ENT”) medical technology leader dedicated to transforming patient care, today announced that Helios Dr. Horst Schmidt Kliniken Wiesbaden in Germany was the first hospital outside the United States to offer the Company’s PROPEL® Contour (mometasone furoate) sinus implant following functional endoscopic ...
-
Lyra Therapeutics to Highlight LYR-210 and LYR-220 Clinical Programs at Virtual Event with Leading Clinical CRS Experts
Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company leveraging its proprietary XTreo™ platform to enable precise, sustained, and local delivery of medications to the ear, nose and throat (ENT) passages and other diseased tissues will host a virtual event with leading chronic rhinosinusitis (CRS) experts to highlight the Company's LYR-210 and LYR-220 clinical ...
-
Lyra Therapeutics Presents New Positive Phase 2 LANTERN 6-Month Follow-Up and LYR-210 Pharmacokinetic Data, and LANTERN Manuscript Wins Award at the 67th Annual Meeting of the American Rhinologic Society
LYR-210 pharmacokinetics indicate a constant and steady daily dose of Mometasone Furoate is delivered to patients LANTERN study manuscript wins ARS Annual Meeting 2021 Clinical Science Maurice Cottle Award Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company leveraging its proprietary XTreo™ platform to enable precise, sustained, and local delivery of ...
-
Lyra Therapeutics Announces Publication of Positive LANTERN Results in the International Forum of Allergy & Rhinology
Company to Initiate Phase 3 ENLIGHTEN Program around YE’21 Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company leveraging its proprietary XTreo™ platform to enable precise, sustained, and local delivery of medications to the ear, nose and throat (ENT) passages and other diseased tissues, today announced that the positive results of the Company’s Phase ...
-
Lyra Therapeutics Announces Four Abstracts Selected for Presentations at Upcoming ERS and ARS Meetings, Including New LANTERN 6-Month Follow-Up and Pharmacokinetic Data
Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company leveraging its proprietary XTreo™ platform to enable precise, sustained, and local delivery of medications to the ear, nose and throat (ENT) passages and other diseased tissues, today announced that four abstracts highlighting LYR-210 results in chronic rhinosinusitis and the XTreo™ platform have been ...
-
Understanding the Difference between COVID-19 Symptoms and Sinus Disease World Sinus Health Awareness Day 2021
The American Academy of Otolaryngology–Head and Neck Surgery (AAO-HNS), in partnership with Intersect ENT, Inc., launched a public education campaign that provides clinically-developed information by experts in the field aimed at helping people better understand their nasal and sinus symptoms. World Sinus Health Awareness Day, with its inaugural celebration on September 29, has an ...
-
Lyra Therapeutics Announces Publication of Preclinical Pharmacokinetics and Drug Release characterization for XTreo™ Technology Platform in the American Journal of Rhinology & Allergy
Outcomes supported advancing into clinical development for LYRA’s first indication, Chronic Rhinosinusitis, with lead product candidate, LYR-210, currently poised to enter Phase 3 studies Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company leveraging its proprietary XTreo™ platform to enable precise, sustained, and local delivery of medications to the ear, ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you